Table 4

Range of net costs and QALYs resulting from scenarios and one-way sensitivity analyses

QALY or cost per person

Item varied



Base case (per person):

not applicable

not applicable

QALY gain 0.013

Net cost -£317 (ie cost saving for enoxaparin)

Event free time gained

0.004 QALYs

0.014 QALYs

Quality of life associated with event

0.012 QALYs


Treatment duration



Length of stay

Difference in length of stay

£42 (ie £3,305/QALY)


Cost per length of stay




Difference in coronary artery bypass grafting rates



Difference in angioplasty rates



Cost of coronary artery bypass grafting



Cost of angioplasty



Unfractionated heparin costs

Unfractionated heparin loading dose and saline flush



Unfractionated heparin drawn-up in saline






Monitoring (activate partial thromboplastin time tests)



Nursing time



Enoxaparin costs



Scenario 3: Treatment of cardiac events

(not mean length of stay)

Myocardial infarction rate and recurrence of angina



Cost to treat acute myocardial infarction



Cost to treat angina



Notes: See Table 2 for ranges used. As there was little difference between scenarios 1 and 2, we amalgamated the results. Negative net costs indicate cost saving if using enoxaparin. Net costs and QALY gains are not shown where unaffected by parameter changes. na means not avaliable.

Nicholson et al. BMC Cardiovascular Disorders 2001 1:2   doi:10.1186/1471-2261-1-2

Open Data